| 1 |
Landriscina M, Amoroso MR, Piscazzi A, et al. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy[J]. Gynecol Oncol, 2010, 117(2):177-182.
|
| 2 |
Elpek GO, Karaveli S, Simsek T, et al. Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries[J]. APMIS, 2003, 111(4):523-530.
|
| 3 |
Wang Q, An L, Chen Y, et al. Expression of endoplasmic reticulum molecular chaperon GRP94 in human lung cancer tissues and its clinical significance[J]. Chin Med J (Engl), 2002, 115(11):1615-1619.
|
| 4 |
Tanaka K, Kondoh N, Shuda M, et al. Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas[J]. Biochim Biophys Acta, 2001, 1536(1):1-12.
|
| 5 |
Langmár Z, Vleskó G. The potential role of heat shock proteins in the treatment of ovarian cancer[J]. Orv Hetil, 2011, 152(3):92-95.
|
| 6 |
张敏，刘晓民．热休克蛋白与肿瘤的研究进展[J]．中华肺部疾病杂志：电子版，2013，6(6)：60-62.
|
| 7 |
Akerfelt M, Trouillet D, Mezger V, et al. Heat shock factors at a crossroad between stress and development[J]. Ann N Y Acad Sci, 2007, 1113:15-27.
|
| 8 |
Samali A, Cotter TG. Heat shock proteins increase resistance to apoptosis[J]. Exp Cell Res, 1996, 223(1):163-170.
|
| 9 |
Tamura Y, Torigoe T, Kukita K, et al. Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity[J]. Immunotherapy, 2012, 4(8):841-852.
|
| 10 |
何杨．HSP27增强卵巢癌细胞对顺铂耐药的研究[D]．武汉：华中科技大学，2013.
|
| 11 |
王宏宇．卵巢浆液性囊腺癌与交界性囊腺瘤的差异蛋白质组学分析[D]．长春：吉林大学，2010.
|
| 12 |
李雅静，石红．HSP70与突变型P53在卵巢癌中的表达及临床意义[J]．山西职工医学院学报，2012，22(5)：4-8.
|
| 13 |
Stope MB, Koensgen D, Burchardt M, et al. Jump in the fire-heat shock proteins and their impact on ovarian cancer therapy[J]. Crit Rev Oncol Hemato, 2015, 97:152-156.
|
| 14 |
Bodzek P, Partyka R, Damasiewicz-Bodzek A. Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer[J]. J Ovarian Res, 2014, 7:30.
|
| 15 |
Kang HJ, Moon HS, Chung HW. The expression of FAS-associated factor 1 and heat shock protein 70 in ovarian cancer[J]. Obstet Gynecol Sci, 2014, 57(4):281-290.
|
| 16 |
Hoffman-Goetz L, Spagnuolo PA. Effect of repeated exercise stress on caspase 3, Bcl-2, HSP 70 and CuZn-SOD protein expression in mouse intestinal lymphocytes[J]. J Neuroimmunol, 2007, 187(1-2):94-101.
|
| 17 |
Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target[J]. Fibrogenesis Tissue Repair, 2012, 5(1):7.
|
| 18 |
Takeuchi K, Nakajima M, Miyazaki T, et al. Is p53 and heat shock protein 70 expression a useful parameter for preoperative hyperthermoradiation therapy in advanced rectal carcinoma[J]. Hepatogastroenterology, 2007, 54(74):367-372.
|
| 19 |
Akyol S, Gercel-Taylor C, Reynolds LC, et al. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling[J]. Gynecol Oncol, 2006, 101(3):481-486.
|
| 20 |
Suzuki M, Matsushima-Nishiwaki R, Kuroyanagi G, et al. Regulation by heat shock protein 22 (HSPB8) of transforming growth factor-alpha-induced ovary cancer cell migration[J]. Arch Biochem Biophys, 2015, 571:40-49.
|
| 21 |
Pavan S, Musiani D, Torchiaro E, et al. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor[J]. Int J Cancer, 2014, 134(6):1289-1299.
|
| 22 |
宋晓敏．分泌型热休克蛋白90α在肿瘤发生和转移中的作用机理[D]．北京：清华大学，2010.
|
| 23 |
Elstrand MB, Stavnes HT, Trope CG, et al. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions[J]. Hum Pathol, 2012, 43(4):529-535.
|
| 24 |
Song TF, Zhang ZF, Liu L, et al. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910)[J]. J Int Med Res, 2009, 37(5):1375-1388.
|
| 25 |
Yang X, Wang J, Zhou Y, et al. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells[J]. Cancer Lett, 2012, 321(2):137-143.
|
| 26 |
Milicevic ZT, Petkovic MZ, Drndarevic NC, et al. Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma-immunohistochemistry and Western blot analysis[J]. Neoplasma, 2007, 54(1):37-45.
|
| 27 |
Sugimura M, Sagae S, Ishioka S, et al. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone[J]. Oncology, 2004, 66(1):53-61.
|
| 28 |
Afanasyeva EA, Komarova EY, Larsson LG, et al. Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70[J]. Int J Cancer, 2007, 121(12):2615-2621.
|
| 29 |
Yang L, Li H, Jiang Y, et al. Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells[J]. Cancer Lett, 2013, 336(1):213-221.
|
| 30 |
Zhao M, Ding JX, Zeng K, et al. Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer？[J]. Tumour Biol, 2014, 35(2):1051-1056.
|
| 31 |
Calderwood SK, Murshid A, Gong J. Heat shock proteins: conditional mediators of inflammation in tumor immunity[J]. Front Immunol, 2012, 3:75.
|
| 32 |
Li D, Li H, Zhang P, et al. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity[J]. Eur J Immunol, 2006, 36(5):1324-1336.
|
| 33 |
Gong J, Zhang Y, Durfee J, et al. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use[J]. J Immunol, 2010, 184(1):488-496.
|
| 34 |
Yuan J, Kashiwagi S, Reeves P, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma[J]. J Hematol Oncol, 2014, 7:15.
|
| 35 |
杨淑莉，金月梅，付莉，等．负载gp96多肽复合物的树突状细胞抗耐药卵巢癌细胞株作用的实验研究[J]．中国妇幼保健，2008，23(33)：4759-4762.
|
| 36 |
Olejek A, Damasiewicz-Bodzek A, Bodzek P, et al. Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma[J]. Int J Gynecol Cancer, 2009, 19(9):1516-1520.
|
| 37 |
Zhang Z, Xie Z, Sun G, et al. Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells[J]. Int J Clin Exp Med, 2015, 8(5):6687-6701.
|
| 38 |
Han FF, Li L, Shang BY, et al. Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair[J]. Asian Pac J Cancer Prev, 2014, 15(17):7043-7048.
|
| 39 |
孙广宇．格尔德霉素及其顺铂联合应用对人卵巢癌细胞SKOV3及SKOV3/DDP耐药性影响的研究[D]．石家庄：河北医科大学，2012.
|
| 40 |
Oude Munnink TH, Korte MA, Nagengast WB, et al. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft[J]. Eur J Cancer, 2010, 46(3):678-684.
|
| 41 |
Vesci L, Milazzo FM, Carollo V, et al. Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor[J]. Int J Oncol, 2014, 45(4):1421-1429.
|
| 42 |
Li W, Wang W, Dong H, et al. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78[J]. Oncol Rep, 2014, 31(6):2525-2534.
|
| 43 |
Elstrand MB, Kleinberg L, Kohn EC, et al. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma[J]. Int J Gynecol Pathol, 2009, 28(3):211-221.
|
| 44 |
Lv Q, Sun H, Cao C, et al. Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer[J]. Tumour Biol, 2016, 37(2):2721-2727.
|